Ananyeva N M, Tischenko V A, Bespalova J D, Pekelis B L, Yakubov L Z, Vinogradov V A, Rokhlin O V, Titov M I
National Cardiology Research Center, Academy of Medical Sciences, Moscow, U.S.S.R.
Immunol Lett. 1988 Aug;18(4):269-73. doi: 10.1016/0165-2478(88)90173-3.
Monoclonal antibodies (MABs) to a new drug Dalargin (Tyr-D-Ala-Gly-Phe-Leu-Arg) enhancing ulcer healing have been produced. Dalargin is a synthetic analog of Leu-enkephalin. With about 40 compounds tested in competition radioimmunoassay it has been shown that specificity of the MABs is directed against the N-terminal tetrapeptide of the molecule. The MABs are sensitive to amino acid substitutions in any of the positions of the fragment and have no cross-reactivity with endogenous opioids. Their further application in pharmacokinetic studies in humans and for characterization of opioid receptors is discussed.
已制备出针对一种促进溃疡愈合的新药达来argin(酪氨酰-D-丙氨酰-甘氨酰-苯丙氨酰-亮氨酰-精氨酸)的单克隆抗体(MABs)。达来argin是亮氨酸脑啡肽的合成类似物。通过在竞争放射免疫分析中对约40种化合物进行测试,已表明这些MABs的特异性针对该分子的N端四肽。这些MABs对该片段任何位置的氨基酸取代都敏感,且与内源性阿片样物质无交叉反应。讨论了它们在人体药代动力学研究及阿片样物质受体表征方面的进一步应用。